The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio.

Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi plans on continuing Vicebio’s scheduled pipeline of vaccines, including Vxb-241, which is currently in Phase 1 study for older adults. Vxb-251, a preclinical trivalent vaccine candidate targets ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine candidates to expand its respiratory syncytial virus (RSV) pipeline beyond mRNA.

Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK.